2026 EBIT break-even depends on Nefecon policy, generic-drug partnership, and new product ramp-up

Overview

This report summarizes Goldman Sachs' key conclusions after discussions with Everest Medicines management at China Healthcare Corporate Day 2026. The report centers on three main themes: pipeline expansion driven by late-stage in-licensed assets, 2026 sales and EBIT break-even guidance constrained by policy and investment, and the company's efforts to maintain its IgAN market leadership through Nefecon-related cooperation with Hainan Herui.

Core views

Goldman Sachs believes Everest Medicines' growth story continues to be driven by Nefecon and a series of in-licensed assets, but short-term profit elasticity does not depend solely on revenue growth. Nefecon faces pressure from anti-corruption policy, NRDL competitors, and generic competition; meanwhile, new products such as Velsipity, Cardamyst, and LNZ100 require commercialization investment. Therefore, although management reiterated its target of full profitability in 2027 and profit above Rmb500mn in 2028, whether 2026 can achieve EBIT near break-even still depends on Nefecon policy outcomes, execution of the generic portfolio strategy, and the speed of new product ramp-up.

Analysis framework

The report combines conference takeaways with company research, making judgments based on management commentary, asset in-licensing progress, sales guidance, cash flow sources, policy impact, and the competitive landscape; the valuation section uses a 10-year DCF through 2036E and derives a 12-month target price of HK$44.02 based on a 12% discount rate and 1% terminal growth rate.

Methodology notes

• Valuation methodology10-year DCF

  Estimates the target price using 2036E as the end of the forecast period, a 12% discount rate, and a 1% terminal growth rate.

  This method is used by Goldman Sachs to calculate Everest Medicines' 12-month target price of HK$44.02, with emphasis on the long-term product portfolio, profitability inflection point, and discounted cash flow.

• Factor frameworkGS Factor Profile

  Compares stocks on a relative basis across growth, financial returns, valuation multiples, and composite percentiles.

  The report discloses Goldman Sachs' factor framework to provide investment context within covered stocks and industry peers, but the core judgment in this report still comes from company meeting takeaways and DCF valuation.

• M&A frameworkM&A Rank

  Goldman Sachs uses a score of 1 to 3 to assess the probability that a covered company could become an acquisition target.

  This framework is part of Goldman Sachs' standard disclosure; if a company is rated 1 or 2, an M&A component may typically be included in the target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Everest Medicines (1952.HK)

  The company covered by the report

  Strengths

  Has a commercialization base including Nefecon and has rapidly added late-stage assets through multiple license-in transactions; cash flow has improved due to the EVER001 upfront payment and Hasten transaction loans.

  Weaknesses

  Its commercialization and manufacturing track record still needs validation, and profitability continues to be affected by new product launch expenses and sales team build-out.

  Comparison

  Rated Neutral in Goldman Sachs' China healthcare coverage universe; return potential should be assessed relative to the coverage group.

  Risks

  Policy impact, IgAN competition, license-in execution, supply chain, and commercialization capability are the main uncertainties.

• Nefecon

  Core IgAN product and key short-term profitability variable

  Strengths

  Remains an important support for the company's market leadership and profit inflection point; after cooperating with Hainan Herui, it can form a dual-product strategy of branded drug plus generic drug.

  Weaknesses

  Faces pressure from anti-corruption policy, potential NRDL inclusion of competing products, and generic pricing pressure.

  Comparison

  Competition in the IgAN market is intensifying, with telitacicep, sibeprenlimab, and CSPC's generic budesonide all approved by the NMPA in 1H.

  Risks

  If pricing pressure cannot be converted into stable market share, Nefecon's revenue and profit contribution may fall short of expectations.

• Cardamyst

  In-licensed late-stage asset, a nasal spray for paroxysmal supraventricular tachycardia

  Strengths

  Management expects approval in 3Q and launch within the year, offering near-term commercialization visibility.

  Weaknesses

  Requires commercialization investment in the early launch stage.

  Comparison

  One of the 8 assets the company has in-licensed since last October.

  Risks

  Approval, launch timing, and sales ramp may fall short of expectations.

• LNZ100

  In-licensed eye-drop asset for presbyopia

  Strengths

  Expands the company's ophthalmology product portfolio.

  Weaknesses

  Still in the launch-preparation and commercialization-investment stage in the short term.

  Comparison

  Together with Cardamyst and Velsipity, it is one source of multi-product launch expenses in 2026.

  Risks

  Commercialization expenses may exceed expectations or market education may progress slowly.

• Lerochol

  Anchor product in the cardiovascular field, a PCSK9 inhibitor

  Strengths

  Its BLA has been accepted by the NMPA, and management views it as a key product in the CVD field.

  Weaknesses

  Commercialization still depends on approval and market access outcomes.

  Comparison

  An important asset for the company's expansion from kidney disease and immunology into the cardiovascular field.

  Risks

  Approval, pricing, and market competition may affect sales realization.

• MT1013

  An SHPT treatment asset for dialysis patients, a CaSR/OGP dual agonist

  Strengths

  In pivotal phase III, with management expecting sales potential of Rmb800mn-1bn.

  Weaknesses

  Clinical and regulatory uncertainties still remain.

  Comparison

  One of the assets with relatively large sales potential in the company's late-stage pipeline expansion.

  Risks

  Phase III results, approval, and commercialization execution may fall short of expectations.

• DMX-200

  A phase III CCR2 inhibitor for FSGS, in-licensed to expand the kidney disease portfolio

  Strengths

  Strengthens the company's specialist positioning in kidney disease.

  Weaknesses

  Still requires validation from clinical results.

  Comparison

  Together with Nefecon and EVER001, it forms the kidney disease product portfolio.

  Risks

  Clinical failure or delayed launch timing.

• EVER001

  A BTK inhibitor out-licensed to Travere Therapeutics

  Strengths

  Brings in a US$112.5mn upfront payment while retaining part of the milestone and sales-sharing rights; its main indications are FSGS and MCD.

  Weaknesses

  Subsequent economic returns depend on Travere's clinical development and commercialization progress, and part of the rights must be shared with Sinovent/SinoMab.

  Comparison

  This is the company's first out-licensing transaction, demonstrating global BD capability.

  Risks

  There is uncertainty around clinical progress, milestone realization, and commercialization sales.

Key data

• Full-year sales guidanceRmb3.5-4bnManagement guidance is below Goldman Sachs' latest forecast of Rmb4.1bn and indicates uncertainty from policy and NRDL impact from competing products.
• 2026 EBIT guidanceNear break-even, approximately ±Rmb100-200mnImproved from FY25's Rmb-386mn, but affected by multi-product launch expenses and commercial team build-out.
• 2027 profitability targetFull profitabilityManagement reiterated its target of achieving full profitability in 2027.
• 2028 profit targetAbove Rmb500mnManagement reiterated its target of profit exceeding Rmb500mn in 2028.
• EVER001 upfront paymentUS$112.5mnThe upfront payment from Travere Therapeutics helps improve cash flow.
• Hasten transaction loan liquidityApproximately Rmb1.5-2bnM&A loans related to the Hasten transaction provide additional liquidity for the company.
• Hasten business contributionApproximately Rmb650-800mnSoutheast Asia sales have been consolidated since July, and China CSO services have been recognized since March.
• Xerava sales contributionRmb300-400mnManagement expects revenue composition to become more diversified, with Xerava as one incremental source.
• MT1013 sales potentialRmb800mn-1bnMT1013 is a CaSR/OGP dual agonist for secondary hyperparathyroidism in dialysis patients and is in pivotal phase III.
• Velsipity sales guidanceSlightly below Rmb100mnManagement stated it will adopt a more aggressive pricing strategy than competitors after NRDL inclusion.
• Nefecon generic cost comparisonApproximately 70% of NefeconThe company stated that Hainan Herui's generic budesonide has lower costs, supporting the branded-drug-plus-generic-drug portfolio strategy.
• Target priceHK$44.02Based on a 10-year DCF, 12% discount rate, and 1% terminal growth rate.

Impact & implications

For investors, the core tension for Everest Medicines lies between the long-term growth optionality brought by its pipeline and BD capabilities and the short-term pressures from Nefecon policy, IgAN competition, and commercialization investment. If Nefecon stabilizes share through the generic partnership and products such as Velsipity and Cardamyst ramp successfully, the 2027-2028 profitability targets will become more visible; if NRDL competition, policy disruption, or launch expenses exceed expectations, the 2026 break-even target may come under pressure.

Risks

• The license-in strategy is affected by external factors, which may cause asset in-licensing, development, or commercialization to fall short of expectations.
• The company lacks a sufficiently proven commercialization and manufacturing track record, and the concentrated launch of new products may amplify execution risk.
• Supply chain disruptions may affect product supply and sales realization.
• Anti-corruption policy, NRDL inclusion of competing products, and intensifying IgAN market competition may suppress Nefecon sales and margins.
• Launch expenses for multiple products such as Velsipity, Cardamyst, and LNZ100 may put pressure on the 2026 EBIT break-even target.

What to watch

• Nefecon's actual sales ramp and pricing performance amid policy, NRDL, and intensifying IgAN competition.
• Whether the Hainan Herui generic budesonide partnership can stabilize market share and expand hospital access.
• Whether Cardamyst can obtain approval in 3Q and launch within the year as planned.
• Velsipity's post-NRDL pricing strategy and sales ramp.
• Progress in consolidating Hasten Biopharmaceuticals' Southeast Asia sales and recognizing its China CSO services.
• Clinical progress in FSGS and MCD for EVER001 with Travere Therapeutics and potential realization of global BD value.
• Changes in the visibility of the targets for full profitability in 2027 and profit above Rmb500mn in 2028.
• Whether the mRNA platform delivers any positive upside surprise.